SEARCH EN EN ABOUT DEVELOPMENT RESEARCH SHARE INFORMATION DOCUMENTATION NEWS CENTER CONTACT HYBRIGENICS, COMMITTED TO BIOPHARMACEUTICAL Research & Development of anticancer drugs Latest press release Research & Development RESEARCH ON DEUBIQUITINATING ENZYMES HIT FINDING LEAD OPT. DUBS One USP Other DUBs DEVELOPMENT OF INECALCITOL PRECLIN. PHASE 1 PHASE 2 PHASE 3 ORPHAN ADULT LEUKEMIA Chronic Lymphocytic Leukemia Chronic Myeloid Leukemia Acute Myeloid Leukemia PROSTATE CANCER Castrate-Resistant Prostate Cancer Focus on leukemia (Source:Leukemia and Lymphoma Society lls.org) CLL Chronic Lymphocytic Leukemia CML Chronic Myeloid Leukemia AML Acute Myeloid Leukemia ALL Acute Lymphocytic Leukemia AGE Hybrigenics focuses its efforts on adult leukemia CCL from 50 years CML from 65 years AML from 50 years ALL less than 20 years ANNUAL INCIDENCE Adult leukemia are the most frequent ones CCL 32% CML 14% AML 33% ALL 11% SURVIVAL RATE AML is the leukemia with the poorest prognosis CLL 85% CML 63% AML 26% ALL 70% Contact Us Site Map Hybrigenics Services Legal Notice © 2017 - Hybrigenics - Website implemented by : Alteo

ABOUT DEVELOPMENT RESEARCH SHARE INFORMATION DOCUMENTATION NEWS CENTER CONTACT HYBRIGENICS, COMMITTED TO BIOPHARMACEUTICAL Research & Development of anticancer drugs Latest press release Research & Development RESEARCH ON DEUBIQUITINATING ENZYMES HIT FINDING LEAD OPT. DUBS One USP Other DUBs DEVELOPMENT OF INECALCITOL PRECLIN. PHASE 1 PHASE 2 PHASE 3 ORPHAN ADULT LEUKEMIA Chronic Lymphocytic Leukemia Chronic Myeloid Leukemia Acute Myeloid Leukemia PROSTATE CANCER Castrate-Resistant Prostate Cancer Focus on leukemia (Source:Leukemia and Lymphoma Society lls.org) CLL Chronic Lymphocytic Leukemia CML Chronic Myeloid Leukemia AML Acute Myeloid Leukemia ALL Acute Lymphocytic Leukemia AGE Hybrigenics focuses its efforts on adult leukemia CCL from 50 years CML from 65 years AML from 50 years ALL less than 20 years ANNUAL INCIDENCE Adult leukemia are the most frequent ones CCL 32% CML 14% AML 33% ALL 11% SURVIVAL RATE AML is the leukemia with the poorest prognosis CLL 85% CML 63% AML 26% ALL 70% Contact Us Site Map Hybrigenics Services Legal Notice © 2017 - Hybrigenics - Website implemented by : Alteo